PetVivo Holdings, Inc. has entered into an Agreement and Plan of Merger to acquire PiezoBioMembrane, Inc. (PBM), a developer of advanced functional biomaterials and piezoelectric technologies. The transaction, announced on June 24, 2026, will see PBM become a wholly owned subsidiary of Cosmeta Corp., PetVivo's wholly owned operating subsidiary. This acquisition is designed to strengthen PetVivo's intellectual property portfolio and create new opportunities for medical device and therapeutic product development across animal and human health markets.

Under the terms of the merger agreement, PBM shareholders will receive an aggregate of 3,000,000 shares of PetVivo common stock. A portion of this consideration is subject to milestone-based retention and forfeiture provisions aimed at aligning future value creation with the achievement of key development and regulatory objectives. The transaction remains subject to customary closing conditions, including the completion of due diligence, satisfaction of specified closing obligations, and the execution of related transaction documents.

The acquisition provides PetVivo with access to PBM's technology platform, which includes proprietary know-how, licensed intellectual property rights, patents, patent applications, and trade secrets. Additionally, PetVivo will gain control of biomaterials, formulations, regulatory assets, manufacturing information, and clinical information. These assets are intended to support the development of functional biomaterials, medical devices, and other therapeutic applications.

John Lai, Chief Executive Officer of PetVivo Holdings, stated that the transaction represents a transformative step in the company's long-term growth strategy. He noted that combining PBM's scientific innovation with PetVivo's product development capabilities, commercialization experience, and regulatory expertise could accelerate the advancement of technologies. Lai also highlighted the potential for the combined platform to secure grant funding, research collaborations, and research and development tax credit programs.

Thanh Nguyen, President of PiezoBioMembrane, described the transaction as an exciting milestone reflecting years of scientific development and innovation. He emphasized that PBM has established a functional biomaterials platform with opportunities across a broad range of medical device and therapeutic applications. Nguyen expressed confidence that combining PBM's technology with PetVivo's capabilities would accelerate future product development and maximize the value of the available intellectual property rights.

Transaction Details

The transaction also establishes a framework for the continued involvement of key PBM personnel in advancing the technology platform and achieving development milestones following the closing. The parties expect the combined resources of PBM, Cosmeta, and PetVivo to accelerate product development activities, regulatory advancement, strategic collaborations, and commercialization initiatives.

PetVivo Holdings, Inc. (OTCQX: PETV) (OTCID: PETVW) will present at the Life Sciences Investor Forum on June 24, 2026, providing investors with insights into its medical device and therapeutic solutions for animals. Chief Executive Officer John Lai is scheduled to deliver the presentation during the live, interactive online forum hosted by VirtualInvestorConferences.com. The event offers a platform for investors and industry professionals to engage directly with management in real time.

The presentation is set to begin at 12:00pm ET on June 24, 2026. A replay of the webcast will be made available following the conclusion of the conference. Additionally, the company has opened a window for one-on-one meetings, which will be available from June 24, 2026, through June 30, 2026. Investors are encouraged to pre-register and perform a system check to ensure smooth participation.

PetVivo focuses on veterinary medical technology, with its flagship product being Spryng with OsteoCushion Technology. This veterinarian-administered intra-articular injection is designed to restore joint mechanics and manage conditions such as lameness and osteoarthritis in dogs, cats, and horses. The company continues to expand its commercialization efforts and international distribution initiatives.

Recent developments for PetVivo include Health Canada's recognition of Spryng as a veterinary medical device and the launch of PetVivo AI initiatives. The company leverages a portfolio of twelve patents and six trade secrets to protect its biomaterials and production processes. Its product pipeline also includes PrecisePRP, an off-the-shelf platelet-rich plasma product for veterinarians.

Virtual Investor Conferences (VIC) specializes in providing interactive forums for publicly traded companies to present directly to investors. The platform replicates the components of an on-site investor conference, offering enhanced capabilities for connecting with retail and institutional investors globally.